Latest Valuation News

Finbar Group Limited reported a robust 46% increase in revenue to $284.5 million for FY2025, despite a 12.5% decline in comprehensive profit. The company completed key residential projects and sharpened its focus on core property development in Western Australia.

Euroz Hartleys Group Limited reported a robust 87.7% increase in net profit for FY25, driven by growth across brokerage, underwriting, and wealth management. The company declared a fully franked full-year dividend of 5.5 cents per share, reflecting confidence in its operational leverage and balance sheet strength.

Harmoney Corp has delivered a record FY25 performance, exceeding profit expectations and boosting its FY26 profit forecast by 20%, driven by strong loan growth and its advanced Stellare 2.0 platform.

Patronus Resources has secured shareholder approval for a selective buy-back, signaling a strategic move to optimise its capital structure and potentially enhance shareholder value.

Xstate Resources has received pre-approval to acquire a 51% stake in the Diona project, setting the stage for drilling operations and ASX trading resumption by late September.

Astron Corporation has completed its redomicile from Hong Kong to Australia, launching Astron Limited (Aus NewCo) as the new ASX-listed parent company with a 2-for-1 share consolidation.

Magellan Financial Group has updated its dividend announcement, correcting the fully franked total dividend to 46.9 cents per share, significantly higher than initially stated. This adjustment reflects a robust payout comprising final, performance fee, and special dividends.

WAM Strategic Value Limited has declared an increased fully franked dividend following an 8.6% rise in its investment portfolio for FY2025, showcasing resilience amid market volatility.

Marquee Resources has successfully closed an oversubscribed $2.51 million placement, underscoring strong investor confidence as it prepares for the next phase of drilling at its Mt Clement Antimony Project.

Vicinity Centres reported a robust FY25 with statutory net profit surging to $1 billion, driven by strategic portfolio repositioning and strong retail sales growth. The company’s focus on premium assets and disciplined capital management sets the stage for continued growth in FY26.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Vicinity Centres has reported a robust increase in revenue and net profit for FY25, alongside a steady distribution payout to securityholders. The company’s financial health shows promising resilience amid a competitive real estate market.